Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2009

Health Discovery Enters Deals with Abbott and Quest Diagnostics for Prostate Cancer Tests

  • Health Discovery (HDC) inked two separate agreements related to its prostate cancer diagnostic program. It has given Abbott the right to commercialize its gene-based tests for clinically significant prostate cancer.

    Abbott acquired coexclusive clinical laboratory rights and exclusive in vitro diagnostic rights for HDC’s tissue-based and urine-based prostate cancer test.

    Additionally, HDC licensed rights to Quest Diagnostics for the development of a urine-based test for clinically significant prostate cancer. Under the terms of this agreement, HDC will receive payments, royalties, and additional undisclosed financial considerations.

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »